INTRODUCTION
was found to be useful as supplement in treatment of various pathologies such as gastric and dermatological disorders, AIDS, cancer and asthma, after conducting both in vitro and in vivo studies in experimental models. [6] [7] [8] [9] [10] [11] [12] Another in vitro study conducted on Herpes simplex virus with mangiferin showed that it has the capacity to inhibit the replication of HSV-1 and HSV-2 viruses within the cells and even to antagonize the cytopathic effects of HIV. [13] [14] [15] Many other in-vitro studies conducted in various cancer cell lines exhibited it's anticancerous activity in inhibiting the proliferation and inducing apoptosis of cancer cell lines, suggesting the potentiality of mangiferin as a chemo preventive agent. [16] [17] [18] [19] The stem bark extract of MI has also found to possess antiplasmodial and antipyretic activity. [20, 21] The regulatory standard of this drug has been mentioned as monograph in the 7 th volume of Homoeopathic Pharmacopoeia of India (HPI), 1999. The proving of the drug Mangifera indica Linn, was conducted by the CCRH in 1995-1996 using double blind method. The drug was proved in 6CH and 30CH potencies in ascending order. The proving was carried out at (i) Regional Research Institute, New Delhi, (ii) Drug Proving Research Unit, Ghaziabad (Uttar Pradesh). Seventeen (17) provers in the age group of 18-49 years had taken part in the proving including three females. [22] This paper presents the symptom compendium of Mangifera indica Linn verifi ed clinically under the councils Clinical Verifi cation Programme.
MATERIALS AND METHODS
The study was conducted between 2005-2010 in 5 centres of CCRH: Homoeopathic Drug Research Institute, Lucknow; Regional Research Institute(H), Shimla; Regional Research Institute(H), Imphal; Dr. D. P. Rastogi Central Research Institute(H), Noida and Clinical Verification Unit(H), Vrindaban.
As per the inclusion criteria, the patients from all age groups, both sexes, having symptomatic similarity with Mangifera indica, and persons willing to participate were included in the study. If patient was taking any acute medicine, he/she was included in the study after a wash-out period of one week. Patients unwilling to participate, having a clinical presentation not corresponding with the study medicine, patients on regular medication for any systemic diseases and patients under chronic medicinal treatment were excluded from the study.
The study medicine was procured from a Good Manufacturing Practice (GMP) compliant homoeopathic pharmacy of India in various potencies, viz. 6C, 30C, 200C and 1M and was distributed to above mentioned institutes/units. After recording the presenting signs and symptoms of the patients in case recording proforma, the symptoms were repertorized using a repertory prepared for clinical verifi cation by CCRH and then a specially developed Materia Medica was consulted for fi nal selection of the remedy. If the presenting symptoms of the case corresponded with the symptomatolgy of Mangifera indica, then the medicine was prescribed in 6C potency and was repeated three times a day, till improvement/aggravation occurred when the drug was stopped; otherwise it was continued for 5/7 days allowing the drug to act. Then the subsequent potencies like 30C, 200C, 1M were prescribed following the guidelines defi ned in the protocol. In cases of improvement under action of any of the above mentioned potencies, Placebo was prescribed so far the improvement continued. If the improvement stopped, i.e., if the case relapsed or became standstill, then the prescription was repeated in same potency. In no case the same potency was repeated for more than two times. In cases where aggravation of the presenting symptoms resulted under trial without any relief, then change of medicine was considered. When new symptoms appeared after administration of the medicine, and if these new symptoms were mild and did not cause much concern to the patient, placebo was prescribed for one week. But if no improvement followed or worsening occurred after one week, then change of medicine was considered. If the new symptoms were severe and cause considerable discomfort to the patient from the beginning, then change of medicine/therapy was considered at once.
In cases where no perceptible improvement occurred after adequate repetition of medicine in different potencies, then it was searched for any obstacle(s) to cure and steps were taken to remove it (when identifi ed) as far as possible. In cases where no response was achieved even after removal of probable obstacle(s), the case was referred for appropriate medical care.
The cases were followed up and assessed once a week or even earlier, if required.
Each and every case has been evaluated in depth to fi nd out any known causative factors to fi nd out the etiological factors and also any obstacle to recovery whether present or not which may hinder the action of the drug and once found, efforts were made to remove/minimize them. A nutritious, well balanced, healthy diet was recommended, as it can help in balancing of immune system. 'Clinical success' was defi ned a priori as cases showing clinical improvement, objective or subjective, of present complaint(s) as judged by the investigating physician(s) and/or as reported by the patient(s). 'Clinical failures' were such cases showing no change and/or worsening or deterioration of the condition, or cases requiring change of medicines/therapy. All the data were collected and compiled in specially designed excel spreadsheet for analysis. Data were presented using descriptive statistics -mean, standard deviations (SD), absolute values, percentages and 95% confi dence intervals (CI). As a rule of thumb, a minimum of two prescriptions for each symptom have been considered for pick-listing. Prevalence of the symptoms in the responding and non-responding population was compared using Chi Square test, keeping P value less than 0.05 (two tailed) as statistically signifi cant.
RESULTS
A total of 114 patients were enrolled in the study having similar 'symptomatology' of Mangifera indica, and meeting the pre-specifi ed eligibility criteria. Of these, 37 cases were dropped out and 77 complete cases were analysed [ Figure 1 ]. The socio demographic information of these patients is given in Table  1 . Clinical success and failure was judged subjectively by the treating physicians. "Clinical success" in 65 cases (84.41%), and "Clinical failure" was observed in 12 cases (15.59%).
The clinically verifi ed symptoms were enlisted along with the outcomes on the basis of existing proving records and the symptoms available in other literature, and also the new clinically observed symptoms or traits, those are not mentioned elsewhere. Among the completed cases, 41 cases (53.25%) were male, 36 cases (46.75%) were females. The mean age of the patients was 28.61 years (SD = 19.05). The patients enrolled were from all age groups but majority were from 16-30 years (n = 31, 40.26%). 74 patients (96.10%) were Hindu, 42 were single (54.55%) and 26 patients (33.77%) were married. No. of student patients were more than of other category (n = 30, 38.96%) [ Table 5 ]. The mean height and weight of the patients were 145.09 cm (n = 64; SD = 26.08) and 48.01 kg (n = 65; SD = 14.02) respectively. The mean SBP and DBP were 118.06 (n = 62, SD = 11.51) and 75.89 (n = 62, SD = 6.42) respectively [ Table 6 ]. Majority of patients have had normal BMI (n = 35, 54.69%) [ Table 7 ]. Among the 65 cases who responded well to Mangifera indica, a total of 10 clinical conditions or diagnosis were obtained; with "Acute upper respiratory tract infection" being the commonest (n = 20, 30.77%) [ Table 8 ].
Among the proving symptoms of CCRH, the followings were most frequently observing symptoms with prevalence rate higher in responding population than in the non-responding population. 1. Coryza with watery nasal discharge (prevalence in responding population: n = 35 (53.85%); 95% CI = 0.42, 0.65) 2. Coryza with heaviness of head (prevalence in responding population: n = 11 (16.92%); 95% CI = 0.09, 0.28) 3. Appetite diminished (prevalence in responding population: n = 11 (16.92%); 95% CI = 0.09, 0.28) 4. Pain in joints, better from pressure (prevalence in responding population: n = 5 (7.69%); 95% CI = 0.03, 0.17) 5. Fever with chill and body-ache (prevalence in responding population: n = 5 (7.69%); 95% CI = 0.03, 0.17).
Among the existing symptoms from other literatures, the most frequently observed symptom were: 1. Skin of face dark as if sunburn and swollen (Prevalence in responding population: n=16 (24.7); 95% CI=0.16-0.36) 2. White spots on skin (Prevalence in responding population: n=2 (3.1%); 95% CI=0.008-0.1)
But the prevalence of these symptom were found higher in non responding population [n=5 (41.7%), 95% CI= 0.19-0.68 & n=2(16.7), 95% CI= 0.05-0.45] Among the new clinical symptoms observed during verifi cation, the most frequently observed symptoms with prevalence rate higher in responding population than in the non-responding population were: 1. Dry cough, agg. at night (prevalence in responding population: n = 4 (6.15%); 95% CI = 0.02, 0.15) 2. Pain in throat while talking (prevalence in responding population: n = 3 (4.62%); 95% CI = 0.01, 0.13).
During Clinical verifi cation of Mangifera indica, it has been observed that patients with some distinct character have responded well to the prescribed drug. These distinct features though have not been modifi ed under the action of the drug in trial (hence cannot be classifi ed under Clinical Symptoms) in the present study, but may come out as important personal characteristics in future studies. These distinct features are given below along with their prevalence in responding population which have been found higher than the non-responding population. 1. Desire for Salty food (prevalence in responding population: n = 15 (23.08%); 95% CI = 0.14, 0.34) 2. Thermal reaction -Chilly (prevalence in responding population: n = 22 (33.85%); 95% CI = 0.24, 0.46) 3. Thermal reaction -Ambithermal (prevalence in responding population: n = 23 (35.38%); 95% CI = 0.25, 0.48) 4. Tongue-clean & moist (prevalence in responding population: n = 51 (78.46%); 95% CI = 0.67, 0.87) 5. Memory weak, forgetfulness (prevalence in responding population: n = 9 (13.85%); 95% CI = 0.07, 0.24).
There were altogether 57 symptoms, where the prevalence rate in responding population was found higher than the prevalence rate in non-responding population. But the prevalence of these symptoms in the responding population was not found to be statistically signifi cant (P > 0.05).
DISCUSSION
A total of 71 symptoms were verifi ed which includes CCRH proving symptoms, symptoms from other existing literatures and symptoms identifi ed as new clinical symptoms. Among these 71 symptoms, 54 symptoms were identifi ed where the symptom prevalence was higher in the responding population than the symptom prevalence in non-responding population. But the prevalence of none of these symptoms was found statistically significant. 16 symptoms were verified from CCRH proving symptoms of Mangifera indica; 10 new symptom components of the proving symptoms were also identifi ed and are presented in italics under the respective proving symptoms [ Table 1 ]. Only 4 symptoms were verifi ed from other existing homoeopathic literature [ Table 2 ]. During the study, 41 entire new symptoms (Clinical symptoms) were identifi ed [ Table 3 ]. Some distinct clinical patterns/features were also identifi ed during the study among the responding population due to their higher prevalence [ Table 4 ]; though these features were not modifi ed under the action of the drug and hence cannot be classed with Clinical symptoms, but they may come out as important personal characteristics in future studies when their prevalence in general population and Likelihood ratio will be estimated.
The "Acute upper respiratory tract infection" was found to be the most commonly responded clinical condition followed by "Vitiligo".
At this point of time, Bayesian probability and likelihood ratios (LR) seem to be the mainstay of future homoeopathic research for confirming/validating the accuracy of the symptoms listed under any drug. [23, 24] Retrospective assessment of prevalence and LR of symptoms in good responders could be a mean for better selection of symptoms for prospective research; but feasibility of conducting such retrospective analysis deserves further discussion. Though the prevalence of symptoms of Mangifera indica, can be identifi ed in the good response group of study population through retrospective analysis of available case records, but fi nding out the prevalence of these symptoms in remainder of the general population treated during the study period in those institutes/units of CCRH where the study had been conducted, is not feasible. Hence, formulation of The causal association can be tested prospectively and systematically in all cases using modifi ed Naranjo criteria [25] in future studies.
The overall results generated were contributed by different study sites/units of the Council, indicating enhanced generalizability of the study fi ndings. However, being an observational trial, this study cannot address the threats to various internal validity issues, e. g., absence of matching, randomization and blinding, the placebo effect, spontaneous recovery of symptoms under question, the therapeutic relationship with the clinician (empathy, compassion, social desirability, etc.), the regression effect toward the mean, and use of undisclosed adjuvant treatments, if any.
In this study, we compared responding and not-responding patients for one medicine. This way, we can only get some idea of symptoms that can be further investigated. These could be of great value when compared with similar data of other medicines. However, the prevalence of symptoms should preferably be compared with the whole population. If possible, this can be estimated or derived from literature. [26] The symptom prevalence should necessarily be higher in the responding population than in the whole population to be considered as an indication for the given medicine. The prevalence of any symptom under investigation can probably be best assessed in multi-center drug validation or clinical verifi cation programs that can produce more reliable and generalizable nation-wide data. Some data are already available [26] but still in a nascent state and how far they can be extrapolated to the remaining nations remains a matter subjected to future research.
CONCLUSIONS
This study exhibited a list of clinically verifi ed symptoms of Mangifera indica and warrants further evaluation using enhanced methodological rigor. On many occasions, limited number of prescriptions were generated for specifi c symptoms making interpretation diffi cult. Calculation of LR will enable more accurate and quantitative description of strength of the probable or claimed characteristic symptoms of the drug, based on empirical evidence instead of assumption. So, further confi rmation of the symptoms in larger sample size, analysis of polarity, and prospective estimation of LR of the symptoms using Bayesian statistical methods in routine practice is necessary prior to inclusion of the symptoms in Homoeopathic Materia Medica and Repertory. Prevalencia de síntomas en una cohorte de 65 pacientes que mejoraron con el medicamento homeopático Mangifera indica: estudio observacional abierto multicéntrico de verifi cación clínica.
Resumen
Objetivo: A verifi car clínicamente la 'sintomatología' de Mangifera indica mediante la determinación de los síntomas mejoraron durante la verifi cación.
Materiales y métodos:
Se efectuó un ensayo observacional abierto multicéntrico. En cinco(5) centros del CCRH, se reclutó un total de 114 pacientes que coincidían con el compendio de síntomas disponibles y cumplían los criterios de elegibilidad. El medicamento se prescribió en las potencias 6C, 30C, 200C y 1M, según las necesidades del paciente, aplicando los principios homeopáticos y el protocolo desarrollado por el Council. Los datos recogidos se sometieron a estadísticas descriptivas. Se realizó una comparación de la prevalencia de los síntomas en la población con y sin respuesta aplicando la prueba de chi cuadrado.
Resultados: Del total de los 114 pacientes incluidos en el estudio, se analizaron 77 casos completos y se produjeron 37 retiradas. El análisis demográfi co muestra una relación de varones/mujeres de 41/36 con una edad media de 28,6 años.Según la valoración subjetiva de los médicos, se obtuvo un "éxito clínico" en 65 casos (84,4%) y se produjeron 12 fracasos (15,6%). Como regla general, se consideró un mínimo de dos prescripciones para el seleccionar cada síntoma.
Conclusiones:
Se identifi có un total de 16 síntomas del registro publicado de patogenesias del CCRH; asimismo, se verifi caron 4 síntomas de otras bibliografías y 51 síntomas clínicos / componentes sintomáticos nuevos. Para la confi rmación e inclusión de estos síntomas en las bibliografías homeopáticas es crucial una posterior replicación y la estimación de la relación de probabilidad en el contexto clínico general.
La prévalence des symptômes chez une cohorte de 65 patients s'est améliorée avec le médicament homéopathique Mangifera indica: une étude multicentrique ouverte de vérifi cation clinique sur la base d'observations.

Résumé
Objectif: Vérifi er cliniquement la 'symptomatologie' de Mangifera indica en déterminant l'amélioration des symptômes lors de la vérifi cation. Résultats: Parmi le total de 114 patients inscrits à l'étude, 77 cas complets ont été analysés, car il y avait 37 cas d'abandon. L'analyse démographique montre que le ratio homme-femme était de 41:36, et l'âge moyen de 28,61 ans. Il y a eu un "succès clinique" dans 65 cas (84,41%) et des échecs dans 12 cas (15,59%), jugés subjectivement par les médecins. Un minimum de deux ordonnances ont été prises en compte pour établir la liste de sélection de chaque symptôme en règle générale.
Matériels et Méthodes
Conclusions: Un total de 16 symptômes probants du CCRH ont été vérifi és, 4 symptômes provenant d'autres publications ont également été vérifi és. 51 nouveaux symptômes cliniques/ composants de symptôme ont été identifi és. Davantage de réplication et d'estimation du rapport de vraisemblance dans le cadre de la pratique générale sont essentielles pour la confi rmation et l'inclusion de tels symptômes dans les publications homéopathiques. 
